Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1675248-19-7

Post Buying Request

1675248-19-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide

    Cas No: 1675248-19-7

  • No Data

  • No Data

  • No Data

  • SAGECHEM LIMITED
  • Contact Supplier

1675248-19-7 Usage

Description

3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide, also known as Tofacitinib impurity L, is an impurity of Tofacitinib (T528000). Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3 (Jak3) inhibitor (CP-690,550), which has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases. 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide plays a significant role in the pharmaceutical industry due to its association with Tofacitinib, a drug with various applications.

Uses

Used in Pharmaceutical Industry:
3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide is used as an impurity in the development and manufacturing process of Tofacitinib. Its presence is crucial for ensuring the quality, safety, and efficacy of the final drug product. The compound is utilized for quality control purposes, helping to monitor and maintain the purity of Tofacitinib during its production.
Used in Research and Development:
In the field of research and development, 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide serves as a valuable compound for studying the properties, interactions, and potential applications of Tofacitinib and its related compounds. Researchers can use this impurity to investigate the mechanisms of action, side effects, and potential improvements to the drug's efficacy.
Used in Quality Control and Regulatory Compliance:
3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide is also used in the quality control and regulatory compliance processes within the pharmaceutical industry. It helps ensure that the drug meets the required standards and guidelines for safety, efficacy, and purity. This impurity plays a vital role in maintaining the integrity of the drug development process and ensuring that patients receive safe and effective treatments.

Check Digit Verification of cas no

The CAS Registry Mumber 1675248-19-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,7,5,2,4 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1675248-19:
(9*1)+(8*6)+(7*7)+(6*5)+(5*2)+(4*4)+(3*8)+(2*1)+(1*9)=197
197 % 10 = 7
So 1675248-19-7 is a valid CAS Registry Number.

1675248-19-7Downstream Products

1675248-19-7Relevant articles and documents

Preparation method of tofacitinib impurity

-

Paragraph 0109; 0110, (2019/02/27)

The invention discloses a preparation method of tofacitinib impurity. A synthetic route is as shown in the specification. The preparation method provided by the invention has the advantages that the synthetic process is simple, the products are easy to separate and purify and the purity of the obtained products is as high as 98.0%. Therefore, the obtained compound I, II in the preparation method can be used for the quality research and process research of related products as impurity reference substances of tofacitinib raw medicinal materials and preparations.

Method of preparing Tropsch process for cloth

-

Paragraph 0038; 0039, (2017/04/28)

The invention belongs to the technical field of medicines, and especially relates to a method for preparing tofacitinib. The method for preparing tofacitinib employs a compound with the structural formula shown as (I), and is characterized in that a compound with the structural formula shown as (III) is prepared from the compound I and a compound with the structural formula shown as (V) or a compound with the structural formula shown as (VI), and the compound III is subjected to a dewatering reaction under the condition of adding a dewatering agent, so that the tofacitinib product with the structural formula shown as (IV) is obtained. Tofacitinib is prepared through two new synthetic routines, the raw materials are cheap and easily obtained, the operation process is simple, the intermediate is easily purified, the total yield is high, the production cost is low, and the method is suitable for industrial amplified production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1675248-19-7